Abstract
In this open-label pilot study, the authors evaluated the effect of memantine on the distribution of brain glucose metabolism in four Huntington's disease (HD) patients as determined by serial 18-fluoro-deoxyglucose [F(18)]FDG-PET scans over a period of 3-4 months (90-129 days, with one patient choosing to continue treatment over the 18-month follow-up period). The treatment regimen was well tolerated. No significant differences on neuropsychological parameters before and after treatment were detected; but the patient who continued treatment did not deteriorate at 18 months' reevaluation, whereas the three patients who had stopped treatment after 3 to 4 months had minor progression in all cognitive domains on re-evaluation 12 months after the end of treatment.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | The Journal of Neuropsychiatry and Clinical Neurosciences |
| Vol/bind | 23 |
| Udgave nummer | 2 |
| Sider (fra-til) | 206-10 |
| Antal sider | 5 |
| DOI | |
| Status | Udgivet - 2011 |